- Home
- Equipment
- north america
- immunotherapy
Show results for
Refine by
Immunotherapy Equipment Supplied In North America
133 equipment items found
Manufactured by:BriaCell Therapeutics Corp. based inWest Vancouver, BRITISH COLUMBIA (CANADA)
Bria-IMT™ (developed from a breast cancer cell line) is a patented (USPTO) immunotherapy approach that directly stimulates the body’s own cancer fighting cells to attack and destroy breast cancer tumors. ...
by:Stemline Therapeutics, Inc. based inNew York, NEW YORK (USA)
SL-701 is an immunotherapy designed to direct the immune system to attack targets present on certain malignancies including brain cancer. SL-701 comprises 3 short synthetic peptides that correspond to epitopes of targets including IL-13Rα2, EphA2, and survivin; 2 of these synthetic peptides (IL-13Rα2 and survivin) are mutant and believed to enhance immune activity. ...
Manufactured by:MedGenome Inc. based inCounty of New Castle, DELAWARE (USA)
OncoPeptTUME — A novel in-silico approach to model the tumor microenvironment and predict treatment efficacy and long-term survival benefits for immunotherapy applications. Cancer immunotherapy is now established as a major therapeutic modality. Cancer immunotherapy drugs elicit their anti-tumor immune response in a subset of the treated ...
Manufactured by:AIVITA Biomedical, Inc. based in, CALIFORNIA (USA)
AIVITA’s immunotherapy technology creates personalized vaccines for cancer patients that target and eliminate tumor-initiating cells which are the seed of the disease. Used alone or in parallel with other treatments, AIVITA’s cancer immunotherapy represents a powerful new approach in the search for curative treatments for ...
Manufactured by:Allovate Therapeutics based inNew York City, NEW YORK (USA)
Oral mucosal immunotherapy (OMIT) is a novel form of allergen-specific immunotherapy. Immunotherapy has a 100-year track record of success for respiratory allergies. OMIT improves upon this approach by delivering immunotherapeutic agents to the areas of the oral cavity with the highest likelihood of prompting a decrease in allergy symptoms in ...
by:Metaclipse Therapeutics Corporation based inAtlanta, GEORGIA (US) (USA)
Metaclipse Therapeutics Corporation is developing novel personalized vaccine immunotherapies for cancer. MembrexTM, a proprietary platform approach tailored to each patient and their specific tumor, consists of ‘membrane vesicles’ prepared from a patient’s tumor tissue that Metaclipse modifies with a ‘protein transfer’ method using proven ...
Manufactured by:Hemogenyx Pharmaceuticals plc based inLondon, UNITED KINGDOM
Hemogenyx Pharmaceuticals has constructed Chimeric Antigen Receptor (CAR) programmed T cells, termed HEMO-CAR-T, for the potential treatment of Acute Myeloid Leukemia (AML). HEMO-CAR-T is made using Hemogenyx’s proprietary humanised monoclonal antibody against a target on the surface of AML ...
Manufactured by:TVAX Biomedical, Inc. based inOlathe, KANSAS (USA)
TVAX®’s lead candidate (TVI-Brain-1) is being evaluated for the treatment of brain cancer and targets glioblastomas. The drug candidate has received Fast Track Designation by the US Food and Drug Administration (FDA) to test TVI-Brain-1 in a Phase 2b clinical study for glioblastoma multiforme (GBM). The Fast Track Designation is supported by positive Phase 2 clinical data, as well as ...
by:Metaclipse Therapeutics Corporation based inAtlanta, GEORGIA (US) (USA)
Influenza (Target age 65+) and Influenza+ SARS-C0V-2 ...
Manufactured by:BriaCell Therapeutics Corp. based inWest Vancouver, BRITISH COLUMBIA (CANADA)
We believe our cellular immunotherapy is most effective when the patient’s HLA-type matches the Bria-IMT™ HLA-type. We are engineering 15 unique HLA types (molecules) into Bria-IMT™, collectively referred to as Bria-OTS™, allowing for matching of over 99% of patients with advanced breast cancer. ...
Manufactured by:Intrommune Therapeutics based inNew York, NEW YORK (USA)
Intrommune has developed a novel drug delivery platform—oral mucosal immunotherapy (OMIT)—for the treatment of food allergies. Therapeutic agents are embedding in fully functioning toothpaste so that treatment can be conveniently administered during a patient’s daily toothbrushing ...
Manufactured by:MorphoSys AG based inPlanegg, GERMANY
Tafasitamab (MOR208) is a humanized FC-modified CD19 targeting immunotherapy in clinical development for the treatment of B cell malignancies. CD19 is broadly expressed on the surface of B cells. It is therefore considered as a potential target for the treatment of B cell malignancies, such as non-Hodgkin’s lymphoma (NHL), including diffuse large B cell lymphoma (DLBCL), ...
Manufactured by:TVAX Biomedical, Inc. based inOlathe, KANSAS (USA)
TVAX®’s second candidate (TVI-Kidney-1) is being evaluated for the treatment of kidney cancer and targets stage 4 renal cell ...
by:Sorrento Therapeutics, Inc. based inSan Diego, CALIFORNIA (USA)
Sorrento’s proprietary G-MAB technology, invented by Dr. Ji, is based on the use of RNA transcription for amplification of the antibody variable domains from over 600 donors. In-depth analysis of deep sequencing DNA data showed that the G-MAB library contains more than 10 quadrillion (1016) distinct antibody sequences. This makes it one of the largest fully human antibody libraries in the ...
by:Sorrento Therapeutics, Inc. based inSan Diego, CALIFORNIA (USA)
Sorrento utilizes a proprietary knock-out knock-in (KOKI) technology to modify normal healthy donor derived T cells to genetically engineer them to express the dimeric antigen receptor into T-cell receptor (TCR) alpha chain constant region (TRAC). In this manner, TRAC is knocked out and antigen is knocked into its locus. The Dimeric Antigen Receptor (DAR) utilizes a Fab instead of the scFv ...
Manufactured by:Transgene based inIllkirch-Graffenstaden, FRANCE
A particularly innovative immunotherapy, TG4050 is the lead myvac® candidate. This individualized treatment is based on the specific mutations that are identified in each patient’s ...
Manufactured by:Transgene based inIllkirch-Graffenstaden, FRANCE
BT-001 is the first oncolytic virus from Invir.IO™ and is optimized to act as a Trojan horse. Two specific “weapons” have been integrated into the Vaccinia viral DNA: an anti-CTLA4 antibody, which was developed by BioInvent, and the cytokine GM-CSF, which triggers the body’s immune ...
Manufactured by:Transgene based inIllkirch-Graffenstaden, FRANCE
A new generation of multifunctional oncolytic virus, TG6002 has been designed to combine the mechanism of oncolysis (targeted destruction of the cancer cell) with the production of chemotherapy (5-FU), directly into the ...
Manufactured by:Transgene based inIllkirch-Graffenstaden, FRANCE
TG4001 is an innovative therapy capable of combating papillomavirus-induced cancers. The concept behind TG4001 is to teach the immune system to recognise and destroy the cancer cells expressing HPV-16 antigens, specifically E6 and E7 ...
Manufactured by:Immune Biosolutions Inc. based inSherbrooke, QUEBEC (CANADA)
Leveraging our technology platforms, we hack the immune system of chickens to discover and engineer the next generation of immunotherapies. ...